focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Kanabo inks CBD deal, Taseko boosts production

Thu, 02nd Nov 2023 14:34

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Taseko Mines Ltd - North America-focused mining company - Copper production for third quarter of 2023 totals 35.4 million pounds, up 7.1% from 28.3 million last year. 32.1 million pounds sold, up 5.4% from 26.7 million. Production for nine months ended September 30 totals 88.5 million pounds, up 18% from 70.3 million. Revenue for the quarter increases 60% to CAD143.8 million from CAD89.7 million. Adjusted Ebitda up 84% to CAD62.7 million from CAD34.0 million. Company swings to GAAP net income of CAD871,000 from a CAD23.5 million loss. Says cash balance at September 30 was CAD82 million.

----------

Henderson International Income Trust PLC - London-based investment company - NAV per share at August 31 is 175.7 pence, down from 181.5p at the same time in 2022. NAV total return for year ended August 31 is positive 1.4%, down from 6.3% the previous year. Pretax net return decreases to GBP5.2 million from GBP15.2 million. Company delivers GBP9.0 million investments loss following GBP1.8 million gain. Declares 1.92 pence fourth interim dividend regardless, up from 1.85p last year. Total dividend increases 3.0% to 7.47p. Chair Richard Hills says: "We cannot control the macroeconomic background but we can maintain and follow the company's existing strategy of identifying companies that have the capacity to grow their earnings and dividends over the medium to long term."

----------

Kanabo Group PLC - London-based patient focused healthcare technology and cannabis company - Inks deal with Wokingham, England-based cannabis manufacturer British Cannabis to supply CBD to patients via prescription. Company says the deal will allow doctors to prescribe pharmacy-grade CBD products from the 'CBD by British Cannabis' range via Treat It, Kanabo's online pain management clinic. Kanabo also says that from this month, Treat It will be included in British Cannabis's online medicinal cannabis app Canndr, which enables patients to select and review cannabis medicines, gain consultancy advice and select prescribing clinics. Kanabo Chief Executive Officer Avihu Tamir says: "This partnership is just the beginning, and we hope to announce more expansive collaborations in due course."

----------

Ocean Harvest Technology Group PLC - Theale, England-headquartered producer of seaweed-based ingredients for animal feed - Announces results of study assessing its OceanFeed Poultry product in meat chickens with necrotic enteritis, a disease caused by the overgrowth of clostridium perfringens in a poultry bird's gut. OceanFeed products aim to bind this pathogen. Study was conducted at the Southern Poultry Research Group in Georgia, US. Company says out of 200 chickens, mortality in the group consuming OceanFeed Poultry "reduced significantly" to 33% from 49%. This group also experienced enhanced weight gain and improved intenstinal lesion scores. Company says data "enhances the use case of OFP in the global poultry industry and will be useful data in discussions with customers currently using and/or looking to use OFP."

----------

e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Announces strategic collaboration with fellow Oxfordian data company Arcturis Data Ltd. Deal will integrate Arcturis's Rea-World Evidence platform and analytical expertise with e-therapeutics's HepNet computational biology platform. HepNet will be used to analyse RWE's output "to drive the discovery and development of innovative RNAi medicines for the treatment of [nonalcoholic steatohepatitis] and related disorders." e-therapeutics retains exclusive rights to nominate novel gene targets to prosecute genetic medicines using its GalOmic platform.

----------

StreaksAI PLC - London-based provider of artificial intelligence-based conversational technologies - Launches "highly personalised" AI chatbot service Streaks Companion, which allows for "sophisticated humanlike companionship, mentorship and digital assistant services." Chatbots are designed for private long-term conversations using Natural Language Processing generators including GPT-4. Says companionship "can either be romantic or platonic, designed to increase users' confidence in navigating real-life relationships, it also offers a secure environment for users to build relationship skills and develop new romantic experiences." Users will pay GBP4.99 per 100 interactions. Company also says it has seen promising levels of early sign-ups for its new Streaks Idols service, which launched in late September and currently has 9,135 registered users.

----------

By Emma Curzon, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
16 Oct 2013 11:57

UK WINNERS & LOSERS: Hargreaves Continues To Rise, e-Therapeutics Trips

Read more
16 Oct 2013 08:56

e-Therapeutics Pretax Loss Widens As R&D Expenditure Rises

Read more
30 Sep 2013 18:45

DIRECTOR DEALINGS: E-Therapeutics Exec, Wife Combined Shares Total 1.8M

Read more
24 Jul 2013 15:53

Wife of DS Smith CEO sells 5.6m-pound stake

The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year. The move came on Tuesday, the same day DS Smith released its annual report

Read more
14 May 2013 09:46

e-Therapeutics pleases with pipeline progress

News from biotech company e-Therapeutics about the progress of two clinical trials for its cancer drug pleased the markets on Tuesday. The AIM-listed company provided first findings for the company's ETS2101 drug candidate in Phase I trials in the US for patients with brain cancer and in the UK fo

Read more
14 May 2013 08:04

Tuesday broker round-up UPDATE

Babcock International: Jefferies increases target price from 1080p to 1250p and maintains a buy recommendation. Barratt Developments: Bank of America takes target price from 265p to 325p, while downgrading to neutral. Belgravium Technologies: WH Ireland places both its target price and its neutral

Read more
10 May 2013 07:14

Friday broker round-up UPDATE

Afren: Westhouse Securities initiates with a target price of 160p and a buy recommendation. Ashmore Group: Credit Suisse raises target price from 375p to 440p upgrading from underperform to neutral. Barratt Developments: Citigroup increases target price from 245p to 315p leaving its neutral rating

Read more
19 Feb 2013 16:21

Debenhams Executive Director adds to stake

Michael Sharp, the Executive Director of retail chain Debenhams, has topped up his stake in the group with the purchase of 50,000 shares. Sharp, who has been in his current role since September 2011, bought the shares at 97.20p for a total of £48,598. He now holds 6.2m shares in the company. Debe

Read more
11 Feb 2013 09:15

e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday. Following the proposed issu

Read more
23 Oct 2012 09:23

Tuesday broker round-up

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe

Read more
22 Oct 2012 08:19

Monday broker round-up - UPDATE

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl

Read more
22 Oct 2012 07:53

e-therapeutics produces mixed interims

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug. As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business. The company ha

Read more
15 Mar 2011 17:05

Bramson vehicle buys more shares in F&C

F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new di

Read more
14 Mar 2011 17:19

Wife of outgoing FD sells British Land shares

Diane Roberts, the wife of British Land finance director Graham Roberts, has raised more than £1m by selling more than three-quarters of the couple's stake in the property investor. She sold 191,780 shares at 562.8p each, which raised £1.08m. The couple are left with 50,464 shares in British Land.

Read more
4 Mar 2011 17:03

Shaftesbury boss invests £100,000

Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares la

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.